Business Context and Reporting Period
This Form 8-K Current Report was filed by Rockwell Medical, Inc. on September 23, 2025. The filing reports a material corporate governance event: the appointment of a new senior executive officer effective immediately.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the promotion of Heather Hunter to the position of Senior Vice President and Chief Operating Officer. Ms. Hunter previously served as the Company's Senior Vice President and Chief Corporate Affairs Officer since August 2022.
Management Commentary, Risks, and Unusual Items
The filing details the terms of Ms. Hunter's employment agreement, originally dated August 31, 2022, and amended on May 20, 2025. Key compensation and risk-related provisions include:
- Compensation Structure: Annualized base salary of $323,574 (subject to adjustment) and a target performance bonus of 45% of base salary.
- Equity Grants: An initial grant of options to purchase 60,000 shares of common stock, vesting in equal installments over four years. These were issued outside the stockholder-approved Long-Term Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
- Termination Provisions:
- Death or Disability: Full acceleration of time-based equity awards.
- Termination without Cause or for Good Reason: One year of base salary continuation, COBRA reimbursement for up to one year, and continued vesting of time-based awards for one year.
- Change of Control: If terminated without Cause or for Good Reason during the effective period, Ms. Hunter is entitled to 1x base salary plus a prorated bonus, COBRA reimbursement, and full acceleration of time-based equity awards.
- Restrictive Covenants: Ms. Hunter has executed a standard Employee Confidentiality, Assignment of Inventions, Non-Interference, and Non-Competition Agreement.
Investor Verification Checklist
- Verify the impact of the new COO appointment on the company's operational strategy and product development pipeline.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the status of the 60,000 share option grant and its impact on total share count and dilution.
- Assess the financial implications of the potential severance liabilities outlined in the termination provisions.